←
QIAGEN4,699 posts
QIAGEN avatar✓

QIAGEN ✓

@QIAGEN

#QIAGEN is a leading provider of molecular Sample to Insight solutions. Impressum: qiagen.com/de/trademarks-…

◷ Joined May 2009▧ 1,949 Photos and videos
QIAGEN avatar
QIAGEN@QIAGEN·Oct 22

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer for all outstanding QIAGEN shares at €46.50 per share. Learn more ➡ tinyurl.com/46rkdju4 #QIA #QGEN

Post attachment
QIAGEN avatar
QIAGEN@QIAGEN·Sep 28

We are excited to announce the launch of QIAmini, a compact automated sample preparation system designed for research laboratories processing smaller sample batches. Learn more ➡ tinyurl.com/cbvfkvsb #QIA #QGEN

Post attachment
QIAGEN avatar
QIAGEN@QIAGEN·Aug 27

We are excited to announce the commercial launch of QIAsymphony Connect, our new IVD-compliant platform for automated clinical nucleic acid extraction. Learn more ➡ tinyurl.com/yn25euhe #QIA #QGEN

Post attachment
QIAGEN avatar
QIAGEN@QIAGEN·Aug 11

We are excited to announce that we have received U.S. FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, our first panel for bloodstream infections in the U.S. Learn more ➡ tinyurl.com/v9dujekx #QIA #QGEN

Post attachment
QIAGEN avatar
QIAGEN@QIAGEN·Aug 5

✅ Full-year 2026 outlook reaffirmed for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER

QIAGEN avatar
QIAGEN@QIAGEN·Aug 5

✅ H1 2026 operating cash of $301 million remains at a strong level compared with H1 2025

QIAGEN avatar
QIAGEN@QIAGEN·Aug 5

➡ Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

QIAGEN avatar
QIAGEN@QIAGEN·Aug 5

➡ Adjusted operating income margin of 29.4%, maintaining a high level of profitability

QIAGEN avatar
QIAGEN@QIAGEN·Aug 5

➡ Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

QIAGEN avatar
QIAGEN@QIAGEN·Aug 5

➡ Net sales of $535 million, unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

QIAGEN avatar
QIAGEN@QIAGEN·Aug 5

We exceed our Q2 2026 outlook, our growth pillars deliver solid sales growth, and we reaffirm our full-year outlook. Learn more ➡ tinyurl.com/298s4y7t #QIA #QGEN

0:20